Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

NCT07027748 is registered in ClinicalTrials.gov with Steven DuBois, MD as lead sponsor.

NCT NCT07027748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07027748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Lead sponsor
Steven DuBois, MD
Phase
Phase 1
Overall status
Recruiting
Start date
June 27, 2025
Completion date
December 1, 2027
Enrollment
18 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

neuroblastoma, neuroblastoma recurrent, refractory neuroblastoma, relapsed neuroblastoma